Artelo Biosciences (ARTL) vs Lakewood-Amedex Biotherapeutics (LABT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Lakewood-Amedex Biotherapeutics is the larger company by market cap ($1.9 million vs $1.8 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ARTL | LABT |
|---|---|---|
| Share price | $3.37 | $0.792 |
| Market cap | $1.85M | $1.88M |
| 1-day change | -1.17% | -6.80% |
| EPS (TTM) | $-136.26 | $-8.83 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $179.19 | $98.20 |
| 52-week low | $3.33 | $0.76 |
| Distance from 52-week high | -98.12% | -99.19% |
| Analyst consensus | — | strong_buy |
| Avg. price target upside | — | +1415.15% |
| Average volume | 480.72K | 2.50M |
| Shares outstanding | 547.77K | 2.37M |
| Employees | 7 | 5 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Artelo Biosciences
ARTL stock →Artelo Biosciences, Inc., a clinical stage biopharmaceutical company, develops and commercializes therapeutics that target lipid-signaling pathways in the United States. The company's product candidate pipeline includes ART27.13, a synthetic dual cannabinoid G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of cancer-related anorexia; and ART12.11, a cocrystal composition of cannabidiol and tetramethylpyrazine for the treatment anxiety, depression, post-traumatic stress disorder PTSD, epilepsy and insomnia, and other potential indications.
Healthcare · Biotechnology · 7 employees
About Lakewood-Amedex Biotherapeutics
LABT stock →Lakewood-Amedex Biotherapeutics, Inc. operates as a clinical-stage biotechnology company that develops antimicrobial products in the United States.
Healthcare · Biotechnology · 5 employees
ARTL vs LABT FAQ
Which is bigger, Artelo Biosciences or Lakewood-Amedex Biotherapeutics?
Lakewood-Amedex Biotherapeutics (LABT) is larger, with a market capitalization of $1.88M compared with $1.85M for Artelo Biosciences (ARTL).
Are Artelo Biosciences and Lakewood-Amedex Biotherapeutics in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.